ACTIV-6: COVID-19 Study of Repurposed Medications

clinical trial

Details

Instance of: clinical trial
Start time: May 2021
End time: December 2022
Country: United States
Main subject: placebo, ivermectin, fluvoxamine, fluticasone, placebo-controlled trial, phase III clinical trial
clinical trial phase: phase III clinical trial
minimum age: 30
number of participants: 15000
research intervention: ivermectin, fluvoxamine, fluticasone
research site: Duke Clinical Research Institute
research subject recruitment status: recruiting
study type: interventional study
title: ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications

Nothing in the MetaHistoryBook collection references this item yet.